How to address second and therapy‐related acute myelogenous leukaemia

Summary Secondary acute myelogenous leukaemia (AML), as compared to de novo AML, occurs in the more elderly population, is independently more resistant to cytotoxic chemotherapy, has a higher relapse rate, and a worse prognosis. Secondary AML (sAML) is a heterogeneous disease, both biologically and...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2020-01, Vol.188 (1), p.116-128
Main Authors: Oliai, Caspian, Schiller, Gary
Format: Article
Language:English
Subjects:
acute leukaemia
Bispecific antibodies
cell therapy
Chemotherapy
Cytotoxicity
Disease resistance
Geriatrics
Grafts
Health risks
Hematology
late effects of therapy
Leukemia
Lymphocytes
Lymphocytes T
Multidrug resistance
myeloid leukaemia
Remission
Stem cell transplantation
Stem cells
Transplantation
tumour immunotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Secondary acute myelogenous leukaemia (AML), as compared to de novo AML, occurs in the more elderly population, is independently more resistant to cytotoxic chemotherapy, has a higher relapse rate, and a worse prognosis. Secondary AML (sAML) is a heterogeneous disease, both biologically and clinically, even within the World Health Organization subgroups of sAML. Outcomes are the poorest in subgroups with sAML arising from an antecedent haematologic disorder which has been previously treated (ts‐AML), and sAML in patients
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.16354